Features | Partner Sites | Information | LinkXpress
Sign In
AB Sciex

Analysis of Molecular Diagnostics Business Published

By Labmedica International staff writers
Posted on 10 Feb 2014
A six-month analysis of the fast-growing molecular diagnostics in vitro diagnostic (IVD) test sector has been published by Kalorama Information
(New York, NY, USA).

Molecular diagnostics is becoming a dominant platform in clinical medicine and it represents one of the fastest growing segments of the diagnostics market. In light of the amount of activity in test development and the regulatory and reimbursement challenges in 2013, the emphasis of the report is on the last 6 months of 2013, July–December. The report provides a breakdown of key market segments for molecular diagnostic markets in world regions, including developed nations and emerging nations.

In the six-month period, trends and developments are highlighted that presage the evolution of molecular tests and technologies. The combination of consumer demand, technological advances, and market forces created a dynamic, energetic, and fast-moving environment for new tests and companies.

Although focused on the developments of the last six months, coverage is substantial. The Kalorama report provides current market size and forecasts for Molecular Diagnostic Segments, including microbiology, histology, blood screening, prenatal, coagulation, inherited diseases, tissue typing, and cancer. A breakdown of key market segments for molecular diagnostic markets in world regions, including developed nations and emerging nations is provided.

In addition the following important trend information is provided: Selected Sequencing-Based Innovations July-December 2013, Selected Molecular Diagnostics collaborations, July-December 2013, Selected Molecular Diagnostics Licensing Agreements, July-December 2013, Selected Molecular Diagnostics Distribution Agreements, July-December 2013, Regulatory and Reimbursement Update and Molecular Test Revenues of the Top Companies, 2012-2013.

Market analysis in this report covers world markets for in vitro diagnostics, but there is a bias toward the developed areas of the globe—North America and Western Europe. However, public health and infectious disease are a growing global problem and where possible the report covers IVD products related to the globalization of diseases. The information presented in the Kalorama report is derived primarily from company reports and other publicly available information published by government and medical organizations.

Related Links:
Kalorama Information



Clinical Chemistry

view channel
Image: The ICON 25 hCG point-of-care pregnancy test (Photo courtesy of Beckman Coulter).

Pregnancy Tests Evaluated During Early Gravidity

The predominant hormone human chorionic gonadotropin (hCG) variant in urine, hCG β core fragment (hCGβcf), has been demonstrated to cause false-negative results in qualitative point-of-care (POC) hCG devices.... Read more

Genetic Tests

view channel
Image: The Quant-iT PicoGreen dsDNA Assay Kit (Photo courtesy of Invitrogen).

Blood Test Provides Rapid Method of Detecting Solid Cancers

Circulating tumor DNA (ctDNA) is a promising biomarker for noninvasive assessment of cancer burden, but existing detection methods have insufficient sensitivity or patient coverage for broad clinical applicability.... Read more


view channel
Image: Micrograph showing prostatic acinar adenocarcinoma, the most common form of prostate cancer (Photo courtesy of Zephron).

New Test Could Accurately Predict Prostate Cancer Recurrence

A test based on genetic signature and tumor oxygen levels, which boost the test’s accuracy, can predict whether a man is at high risk of prostate cancer recurrence. Prostate cancer is the most common... Read more
Copyright © 2000-2014 Globetech Media. All rights reserved.